Roche Holding AG
European markets rally as U.S. inflation rises less than expected, EU retaliates to Trump’s tariffs
U.S. inflation rate hits 2.8% in February, less than expected Prices for goods and services moved up less than expected in February, providing some relief as consumers and businesses worry about the looming impact tariffs might have on inflation, the Bureau of Labor Statistics reported Wednesday. The consumer price index, a wide-ranging measure of costs across […]
Read More
Europe stocks open in the green to extend record high; traders digest dovish ECB messaging
French inflation held at 1.8% in January French inflation came in at 1.8% in January on a preliminary basis, steady on the previous month, statistics agency Insee reported Friday. Economists polled by Reuters expected a reading of 1.9%. The figure is adjusted for comparison with other euro zone countries. National German inflation figures are due […]
Read More
European markets head for higher open anticipating ECB rate cut; Shell and Deutsche Bank earnings on deck
European markets were set to open higher Thursday as investors await key earnings, economic data and the European Central Bank’s latest monetary policy decision. The U.K.’s FTSE 100 index is expected to open 2 points lower at 8,555, Germany’s DAX up 24 points at 21,649, France’s CAC up 25 points at 7,892 and Italy’s FTSE MIB […]
Read More
European markets set to start the new trading week on a somber note
European markets are expected to start the new trading week in negative territory on Monday, with investors in the region gearing up for a busy period of earnings and the European Central Bank’s latest interest rate decision. The U.K.’s FTSE 100 index is expected to open 7 points lower at 8,488, Germany’s DAX down 68 […]
Read More
Want to invest in weight loss drugs? Here’s where UBS thinks they’re headed in 2025
The biopharma sector has been hotly watched among investors over the past two years amid a boost to the industry by the growing popularity of the glucagon-like peptide-1 (GLP-1) drugs used in weight loss treatments. Looking ahead into 2025, however, UBS foresees that the sector “will find it difficult to outperform against a more uncertain […]
Read More
These innovative biotech stocks have a good chance of breaking out in 2025
Trends may be shifting in favor of biotech stocks in 2025 after several years of poor performance, but it would still be wise to place your bets carefully on some of the most innovative names. “We’re still optimistic on the outlook for biotech,” said Stacey Sears, senior vice president and portfolio manager at Emerald Advisors, […]
Read More
Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal
Exterior view of the entrance to Merck headquarters on February 05, 2024 in Rahway, New Jersey. Spencer Platt | Getty Images Merck on Wednesday said it has snagged the rights to an experimental weight loss pill from Chinese drugmaker Hansoh Pharma, in a deal worth up to $2 billion. The oral drug has not yet […]
Read More
Healthy Returns: A huge deal to boost Novo Nordisk’s manufacturing is one step closer to closing
A view of the logo of Novo Nordisk at the company’s office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. Tom Little | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. […]
Read More
European stocks close lower as traders focus on earnings and bond yields
Canada’s central bank cuts interest rates by 50 basis points Canada’s central bank on Wednesday took a big step in easing monetary policy by cutting its key benchmark rate by 50 basis points to 3.75%. The Bank of Canada said it expects the global economy to expand at a rate of about 3% over the […]
Read More
Novartis not joining the ‘frenzy’ of weight loss drugs, CEO says
The CEO of Novartis said Wednesday that the Swiss pharmaceutical giant does not plan to enter into the “frenzy” of weight loss drugs, preferring instead to focus on areas where it can build a “unique position.” Speaking to CNBC, Vas Narasimhan said that the company was researching treatments that deal with the secondary effects of […]
Read More